Cargando…
Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab
Currently, eculizumab is the main effective treatment for paroxysmal nocturnal hemoglobinuria (PNH). The aim of this randomized multicenter noninferiority study was to evaluate the efficacy and safety of the Biosimilar (Elizaria) in comparison with the Originator (Soliris) in patients with PNH. Bios...
Autores principales: | Kulagin, Alexander D., Ptushkin, Vadim V., Lukina, Elena A., Davydkin, Igor L., Korobkin, Alexander V., Shamrai, Vladimir S., Konstantinova, Tatyana S., Kaporskaya, Tatyana S., Mitina, Tatyana A., Ksenzova, Tatyana I., Zuev, Evgeny V., Markova, Oksana A., Gapchenko, Elena V., Kudlay, Dmitry A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510904/ https://www.ncbi.nlm.nih.gov/pubmed/34398258 http://dx.doi.org/10.1007/s00277-021-04624-7 |
Ejemplares similares
-
Serum Uric Acid Predicts Declining of Circulating Proangiogenic Mononuclear Progenitor Cells in Chronic Heart Failure Patients
por: Berezin, Alexander E., et al.
Publicado: (2014) -
The predictive role of circulating microparticles in patients with chronic heart failure()
por: Berezin, Alexander E., et al.
Publicado: (2014) -
The Association of Subclinical Hypothyroidism and Pattern of Circulating Endothelial-Derived Microparticles Among Chronic Heart Failure Patients
por: Berezin, Alexander E., et al.
Publicado: (2015) -
The utility of biomarker risk prediction score in patients with chronic heart failure
por: Berezin, Alexander E., et al.
Publicado: (2016) -
The Mechanisms of the Regulation of Immune Response in Patients with Comorbidity of Chronic Obstructive Pulmonary Disease and Asthma
por: Kalinina, Elena P., et al.
Publicado: (2016)